

Maman Biomedical™



COMPANY

Website: <https://mamanbiomedical.ca/>

Year Established: 2024

Patents/Trademarks: In-progress

Stage: MVP - Validating

Industry: Life Sciences – Fem Tech

E-mail: latchmi@mamanbiomedical.ca

TEAM

Founders and Management Team:

Founder & CEO - Dr. Latchmi Raghunanan, PhD Materials Science. 5 granted patents, 15 peer-reviewed publications, 4 years leading R&D, & IP at a medical device startup.

Superpowers: Strategic thinking & execution

Co-founder & CBO - Roopchand Raghunanan, PMP, PgMP. 20 years governance & executive-level leadership expertise.

Superpowers: High in EQ & Diplomacy

Co-founder & COO - Lauren Franzoni. Life Science, Commerce, and VC expertise.

Superpowers: Gift of Gab & Hypewoman

Board of Advisors:

Reproductive Endocrinologist, Reproductive Biologist, Regulatory Expert, Biomaterials Translational Scientist, MedTech Expert, Lawyer.

FINANCIAL INFO

Revenue: Pre-revenue

Monthly Burn: \$18,000

Funding to Date: \$242,000

Capital Seeking: \$250,000 F&F, Q4 2024

USE OF FUNDS

Strategy: Leverage \$250,000 into \$430,000 through non-dilutive grants.

53% Product Development (Salaries, lab, equipment, consumables, trials).

12% Business Development (Conferences).

8% Operations (Office rent, non-R&D salary, insurance, IT, travel).

27% Legal (IP, accounting, tax).

COMPANY OVERVIEW

Problem: Infertility affects every 1 in 5 couples in North America, and in vitro fertilization (IVF) is a common solution. However, the current IVF standard of care requires upwards of 20 injections over 8-10 days, making the process invasive and uncomfortable.

Value Proposition Statement: We eliminate the pain and inconvenience of repeated injections with our innovative drug delivery solutions, ensuring consistent dosage and minimal impact on lifestyle.

Technology: Maman Biomedical is pioneering slow-release drug delivery systems to revolutionize fertility treatment:

- *Maman Patch™*, our needle-free product that provides consistent hormone delivery without injections; and
- *Maman Gel™*, our single-injection alternative that maintains effective hormone levels for the entire treatment cycle.

Current State of Development: MVP - Prototype testing - validation

MARKET

Target Market: Global IVF Drug Treatment Market, valued at \$25B in 2024 and growing at 6% CAGR.

North American Market Opportunity: *Maman Patch™*: \$1B; *Maman Gel™*: \$3.5B

BUSINESS MODEL AND TRACTION

Revenue Model: Sales to Pharmacies. *Maman Patch™*: premium-priced; *Maman Gel™*: value-priced.

Go to Market Strategy: Partnerships with fertility clinics and doctors established during product development.

Distribution Model/Channel Partners: Licencing agreements with major pharmaceutical manufacturers who will use their established distribution channels to Fertility Clinics and Pharmaceutical suppliers.

Current Traction: Ongoing discussions with 1 potential strategic (Merck), 3 fertility clinics, and 5 Reproductive Endocrinologists; partnership with St. Joes Hospital for clinical trial development; lab space secured; patent and trademark searches completed; \$50k of current Family & Friends (F&F) fundraising round hard-committed.

MILESTONE PLAN

- *Next 3 months:* F&F round closes, Phase 2 R&D commences, Provisional Patent and Trademarks filed.
- *At 6 Months:* Pilot animal study completed; Pre-seed funding round in progress, product feedback and refinement commenced.
- *At 12 Months:* Additions to Provisional Patent filed, Trademarks secured, early pre-clinical validation commenced.

Activities and Resources: Research & Product Development. Resources: 1 Materials Scientist (CEO expertise); 1 Mitacs postdoc (Biology); 2 interns (Chemistry, Clinical); lab space, consumables & freeze-dryer; pilot trial & Key Opinion Leader fee; operations and legal services.



Challenges: We're aggressively raising a back-to-back \$250k Friends and Family round and a \$1.5M Pre-Seed round; we're on the lookout for a lead investor, deep pockets, and follow-on investors.

PARTNERS




How it Works


Day 1 - Dosage administered



8-24 hours later



need to reinject



NO re-administration required